Kymera Therapeutics, Inc. $KYMR Stock: Pictet Asset Management Holding SA Decreases Position

Pictet Asset Management Holding SA lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 24.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 298,928 shares of the company’s stock after selling 96,612 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.36% of Kymera Therapeutics worth $33,363,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in KYMR. GAMMA Investing LLC grew its position in shares of Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Kymera Therapeutics by 236.5% during the 3rd quarter. IFP Advisors Inc now owns 737 shares of the company’s stock worth $82,000 after purchasing an additional 518 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock worth $107,000 after purchasing an additional 463 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Kymera Therapeutics during the 1st quarter worth approximately $203,000. Finally, Nykredit A S acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $207,000.

Insider Activity at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. This trade represents a 11.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KYMR shares. Loop Capital set a $132.00 target price on Kymera Therapeutics in a report on Thursday, October 29th. Piper Sandler reissued an “overweight” rating and set a $140.00 price target on shares of Kymera Therapeutics in a research report on Wednesday, September 23rd. Royal Bank Of Canada boosted their price target on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. Guggenheim upped their price objective on Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Finally, Citigroup increased their price objective on Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $139.16.

Kymera Therapeutics Price Performance

KYMR opened at $136.64 on Wednesday. The stock has a market capitalization of $11.66 billion, a price-to-earnings ratio of -37.75 and a beta of 2.04. The business has a 50-day moving average of $116.45 and a two-hundred day moving average of $98.47. Kymera Therapeutics, Inc. has a 12 month low of $60.25 and a 12 month high of $142.92.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.39%. The company’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.94) EPS. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.